文章：

肿瘤药物免疫介导不良反应的关键决定因素

Key Determinants of Immune-Mediated Adverse Reactions to Oncology Drugs

原文发布日期：28 November 2023

DOI: 10.3390/cancers15235622

类型: Article

开放获取: 是

英文摘要：

To overcome the epidemiological severity of cancer, developing effective treatments is urgently required. In response, immune checkpoint inhibitors (ICIs) have been revealed as a promising resolution for treatment-resistant cancers across the world. Yet, they have both advantages and disadvantages, bringing therapeutic benefits while simultaneously inducing toxicity, and in particular, immune-mediated adverse drug reactions (imADRs), to the human body. These imADRs can be pathogenic and sometimes lethal, hampering health prediction and monitoring following the provision of ICI treatment. Therefore, it is necessary to collectively identify the determinant factors that contribute to these imADRs induced by ICIs. This article evaluated treatment-, tumor-, and patient-related determinants, and indicated a research gap for future investigations on the pathogenic mechanism of imADRs and translational conversion of determinants into clinical biomarkers to aid pharmacovigilance and cancer therapies.

摘要翻译： 

为应对癌症流行病学的严峻挑战，开发有效治疗方案迫在眉睫。在此背景下，免疫检查点抑制剂（ICIs）已被证实是全球范围内治疗耐药性癌症的有效策略。然而，这类疗法兼具利弊：在带来治疗获益的同时，也可能引发毒性反应，特别是免疫介导的药物不良反应（imADRs）。这些imADRs具有潜在致病性，甚至可能危及生命，从而影响ICI治疗后的健康预测与监测。因此，系统识别导致ICI诱发imADRs的决定性因素至关重要。本文评估了治疗相关、肿瘤相关及患者相关的决定因素，并指出未来研究需重点关注imADRs致病机制解析，以及如何将这些决定因素转化为临床生物标志物，以促进药物警戒和癌症治疗优化。

原文链接：

Key Determinants of Immune-Mediated Adverse Reactions to Oncology Drugs